Royalty Pharma (MEX:RPRXN) Total Long-Term Assets: MXN315,045 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
65 GF Score
Price MXN1,025.44
GF Value MXN559.33
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Total Long-Term Assets?

Royalty Pharma MEX:RPRXN 65 Total Long-Term Assets is MXN315,045 Mil as of Jun. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 65/100 and a GF Value™ of MXN559.33 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Royalty Pharma's Total Long-Term Assets for the quarter that ended in Jun. 2026 was MXN315,045 Mil.

Royalty Pharma Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Total Long-Term Assets Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only 300,276.84 277,984.85 256,441.13 342,462.61 325,771.53

Royalty Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 316,382.51 320,982.10 325,771.53 331,614.21 315,045.20
MEX:RPRXN
65GF Score
Royalty Pharma PLC MEX:RPRXN
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of MXN315,045 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Total Long-Term Assets of MXN315,045 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Total Long-Term Assets too high?
Royalty Pharma's current Total Long-Term Assets is MXN315,045 Mil. Overall, Royalty Pharma has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Total Long-Term Assets compare to ROIV and INCY?
Royalty Pharma's Total Long-Term Assets of MXN315,045 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Total Long-Term Assets is MXN315,045 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (MEX:RPRXN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN559.33, compared to a current price of MXN1,025.44 — trading 83.3% above its estimated fair value. The current Total Long-Term Assets is MXN315,045 Mil. Royalty Pharma's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Total Long-Term Assets is MXN315,045 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN1,025.44 is trading 83.3% above its estimated GF Value™ of MXN559.33. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for MEX:RPRXN:

  • Total Long-Term Assets: MXN315,045 Mil
  • GF Value™: MXN559.33 vs. price of MXN1,025.44 (83.3% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
65GF Score

Get the complete analysis for MEX:RPRXN

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,025.44
Price
MXN559.33
GF Value